Correction to: Development of a novel TLR8 agonist for cancer immunotherapy.
作者信息
Wang Yuxun, Yang Heping, Li Huanping, Zhao Shuda, Zeng Yikun, Zhang Panpan, Lin Xiaoqin, Sun Xiaoxiang, Wang Longsheng, Fu Guangliang, Gao Yaqiao, Wang Pei, Gao Daxin
机构信息
Shanghai Denovo Pharmatech Co., Ltd., 576 Libing Road, Shanghai Zhangjiang High-Tech Park, Pudong New District, Shanghai, 201203, China.
出版信息
Mol Biomed. 2021 May 21;2(1):16. doi: 10.1186/s43556-021-00042-3.
PMID:35006462
Abstract
摘要
相似文献
[1]
Correction to: Development of a novel TLR8 agonist for cancer immunotherapy.
Mol Biomed. 2021-5-21
[2]
[3]
Development of a novel TLR8 agonist for cancer immunotherapy.
Mol Biomed. 2020-9-10
[4]
[Expression of TLR8 in human cervical cancer HeLa cells and the effect of TLR8 agonist on the cell proliferation and apoptosis].
Zhonghua Zhong Liu Za Zhi. 2011-9
[5]
[6]
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
J Immunotoxicol. 2009-12
[7]
[8]
[9]
TLR8 agonist partially improves IFN-γ deficiency of NK cells in chronic hepatitis B through the synergy of monocytes.
Aliment Pharmacol Ther. 2023-2
本文引用的文献
[1]
Development of a novel TLR8 agonist for cancer immunotherapy.
Mol Biomed. 2020-9-10
Zotero 插件